CANNABIS SCIENCE INC (OTCMKTS:CBIS) Reports Increase in Sellers; Strong Momentum for Short Players

Cannabis Science, Inc. (OTCMKTS:CBIS) Logo

Investors sentiment decreased to 0 in 2018 Q2. Its down 2.50, from 2.5 in 2018Q1. It fall, as 1 investors sold Cannabis Science, Inc. shares while 0 reduced holdings. 0 funds opened positions while 0 raised stakes. 252,180 shares or 4.54% less from 264,180 shares in 2018Q1 were reported.
Massmutual Com Fsb Adv reported 0% stake. Wesbanco Bank & Trust accumulated 15,000 shares. Neville Rodie And Shaw holds 0% or 20,000 shares. 40,000 were reported by North Star Asset Mngmt Inc. Donaldson Capital Management Limited Liability Corp holds 0% or 99,780 shares in its portfolio. Frontier Investment Mgmt invested in 0% or 20,000 shares. Silvercrest Asset Management Ltd Co holds 0% in Cannabis Science, Inc. (OTCMKTS:CBIS) or 10,000 shares. Moreover, Stonebridge Advsr Limited Liability Co has 0% invested in Cannabis Science, Inc. (OTCMKTS:CBIS). Edge Wealth Mngmt Limited Liability Company stated it has 15,000 shares. Rothschild Inv Corporation Il reported 14,000 shares.

The stock of CANNABIS SCIENCE INC (OTCMKTS:CBIS) registered an increase of 1959.14% in short interest. CBIS’s total short interest was 574,500 shares in November as published by FINRA. Its up 1959.14% from 27,900 shares, reported previously.

The stock decreased 2.31% or $0.0009 during the last trading session, reaching $0.0381. About 3.23 million shares traded. Cannabis Science, Inc. (OTCMKTS:CBIS) has 0.00% since November 14, 2017 and is . It has underperformed by 15.62% the S&P500.

Cannabis Science, Inc., together with its subsidiaries, develops, produces, and commercializes phytocannabinoid pharmaceutical products primarily in the United States. The company has market cap of $104.62 million. The firm is developing medicines for autism, blood pressure, cancer, cancer side effects, and other illnesses, as well as for general health maintenance. It currently has negative earnings. The Company’s drugs under development include CS-TATI-1 for newly diagnosed and treatment-experienced patients with drug-resistant HIV strains, as well as those intolerant of available therapies; CS-S/BCC-1 to treat basal and squamous cell carcinomas; and a proprietary cannabis therapy for neurological conditions.

More news for Cannabis Science, Inc. (OTCMKTS:CBIS) were recently published by:, which released: “30 Marijuana Stocks to Buy as the Future Turns Green” on October 16, 2018.‘s article titled: “Providing Turnkey Infrastructure Solutions to Cannabis Producers” and published on October 24, 2018 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.